ClinicalTrials.gg
CompletedNCT02471560TECONGUTUpdated Sep 5, 2021

Tecfidera and the Gut Microbiota

A Phase 4 interventional study of dimethyl fumarate and injectable MS DMT in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 7 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Biogen · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
14th of 22
36 · median 61
Started
2015
with 5 others
Phase 4
9 of 22
none open now
Registered
15th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 14th largest by enrollment, is one of 6 that started in 2015, is one of 9 in phase 4, and was the 15th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of the study is to determine if dimethyl fumarate (DMF) causes changes in the abundance and diversity of commensal microbiota. The secondary objectives of this study are as follows: To identify if there are differences in the gut microbiota composition between patients that do or do not develop gastro intestinal (GI) adverse events (AEs), both pre- and post DMF treatment and to examine if the resolution of GI AEs in DMF treated patients is reflected in the gut microbiota.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Microbiota
  • DMF
  • Gastro intestinal
  • MS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a confirmed diagnosis of RRMS and satisfy the therapeutic indication as described in the local label.
  • Female subjects of who are not surgically sterile must practice effective according to the summary of product characteristics (SPC) during their participation in the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Key Exclusion Criteria:

  • Diagnosis of primary progressive, secondary progressive or progressive relapsing MS.
  • Antibiotic treatment in the last month prior to study entry.
  • Scheduled alteration of diet, including the use of probiotics.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    dimethyl fumarate

    As prescribed by the Investigator according to the local Summary of Product Characteristics.

    Drug: dimethyl fumarate

  • Active comparator
    injectable MS DMT

    As prescribed by the Investigator according to the local Summary of Product Characteristics.

    Drug: injectable MS DMT

Interventions

  • As per the prevailing local label.

    Also known as: DMF, Tecfidera, BG00012

  • Druginjectable MS DMT

    As described above.

06

What researchers measure

Primary outcomes

  1. Comparison of the change in gut microbiota composition in participants pre vs. post initiation of DMF treatment.

    Time frame: Day 1, Week 2, Week 12 and/or upon occurrence of GI symptoms outside of designated time points

Secondary outcomes

  1. Change in gut microbiota composition between DMF treated participants that do or do not develop GI AEs as measured by an increase in the Gastrointestinal Symptom Rating Scale (GSRS) score.

    GSRS is a self-reported questionnaire regarding GI symptoms comprising 15 items scored on a 7-point Likert scale. The 15 items can be grouped in 5 dimensions 1) abdominal pain (abdominal pain, gastric hunger pain, and nausea) 2) reflux (heartburn and acid regurgitation) 3) indigestion (borborygmus, bloating, eructation, and increased flatus) 4) diarrhea (diarrhea, loose stools, and urgency) and 5) constipation (constipation, hard stools, incomplete evacuation). A GI AE will be defined as an at least 2 point (\>=2) increase from baseline in total score of any of the 5 dimensions in the GSRS.

    Time frame: Day 1, Week 2, Week 12 and/or upon occurrence of GI symptoms outside of designated time points

  2. Changes in gut microbiota composition in participants treated with DMF compared to participants treated with an alternative injectable multiple sclerosis (MS) disease modifying therapies (DMT)

    Time frame: Day 1, Week 2, Week 12 and/or upon occurrence of GI symptoms outside of designated time points

  3. Baseline differences in the gut microbiota composition between DMF treated participants that do or do not develop GI AEs.

    Time frame: Day 1, Week 2, Week 12 and/or upon occurrence of GI symptoms outside of designated time points

  4. Changes in the gut microbiota composition of DMF treated participants after resolution of GI AEs vs. during GI AE occurrences.

    Time frame: Upon GI symptoms and week 12

07

Study locations

7 sites
  • Research site
    Drammen, 3019, Norway
  • Research site
    Haukeland, 5021, Norway
  • Research Site
    Lillehammer, 2609, Norway
  • Research site
    Lørenskog, 1478, Norway
  • Research site
    Molde, 6412, Norway
  • Research site
    Oslo, 0450, Norway
  • Research site
    Stavanger, 4011, Norway
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jun 2017, 19 months.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2015
First posted
Jun 15, 2015
StartActual
Nov 6, 2015
Primary completionActual
Jun 12, 2017
CompletionActual
Jun 12, 2017
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02471560
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Nov 6, 2015
Primary completion
Jun 12, 2017
Completion
Jun 12, 2017
Last update
Sep 5, 2021

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion